Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Oncology|March 1, 1995
Clinical experience with tegafur and low dose oral leucovorin: a dose-finding studyM Nogué, E Saigí, M A Seguí
Cancer|February 1, 1993
Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institutionJ R Germá, A F Sagarra, M A Izquierdo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 1, 1997
Prognostic value of S-phase fraction in lymph-node-negative breast cancer by image and flow cytometric analysisG Peiró, E Lerma, M A Climent, et al.
Cancer Treatment Reviews|July 17, 2012
Finding the right dose of fulvestrant in breast cancerL Estévez, I Alvarez, I Tusquets, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 22, 2009
Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancerM Martín-Jiménez, A Rodríguez-Lescure, M Ruiz-Borrego, et al.
Gynecologic Oncology|May 1, 1992
Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant PauJ R Germá, M A Izquierdo, M A Seguí, et al.
Cancer|July 21, 1998
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinomaM Nogué, M A Seguí, E Saigí, et al.
Breast (Edinburgh, Scotland)|November 18, 2005
HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred casesA Sáez, F J Andreu, M A Seguí, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 studyA Antón, A Ruiz, M A Seguí, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatmentM A Climent, M A Seguí, G Peiró, et al.
Pageof 3